Multi-cancer early detection test sensitivity for cancers with and without current population-level screening options. Issue 3 (June 2023)

• Record Type: Journal Article
• Authors: Shao, Spencer H.; Allen, Brian; Clement, Jessica; Chung, Gina; Gao, Jingjing; Hubbell, Earl; Liu, Minetta C.; Swanton, Charles; Tang, W.H. Wilson; Yimer, Habte; Tummala, Mohan
• Is Part Of: Tumori. Volume 109:Issue 3(2023)
• Page Start: 335
• Page End: 341
• Publication Date: 2023-06
• Subjects: Multi-cancer early detection -- early detection -- cancer screening -- liquid biopsy -- precision medicine -- epidemiology and prevention; Cancer -- Periodicals; 616.994
• DOI: 10.1177/03008916221133136
• Languages: English
• ISSNs: 0300-8916

Abstract

There are four solid tumors with common screening options in the average-risk population aged 21 to 75 years (breast, cervical, colorectal, and, based on personalized risk assessment, prostate), but many cancers lack recommended population screening and are often detected at advanced stages when mortality is high. Blood-based multi-cancer early detection tests have the potential to improve cancer mortality through additional population screening. Reported here is a post-hoc analysis from the third Circulating Cell-free Genome Atlas substudy to examine multi-cancer early detection test performance in solid tumors with and without population screening recommendations and in hematologic malignancies. Participants with cancer in the third Circulating Cell-free Genome Atlas substudy analysis were split into three subgroups: solid screened tumors (breast, cervical, colorectal, prostate), solid unscreened tumors, and hematologic malignancies. In this post hoc analysis, sensitivity is reported for each subgroup across all ages and those aged ⩾50 years overall, by cancer, and by clinical cancer stage. Aggregate sensitivity in the solid screened, solid unscreened, and hematologic malignancy subgroups was 34%, 66%, and 55% across all cancer stages, respectively; restricting to participants aged ⩾50 years showed similar aggregate sensitivity. Aggregate sensitivity was 27%, 53%, and 60% across stages I to III, respectively. Within the solid unscreened subgroup, aggregate sensitivity was >75% in 8/18 cancers (44%) and >50% in 13/18 (72%). This multi-cancer early detection test detected cancer signals at high (>75%) sensitivity for multiple cancers without existing population screening recommendations, suggesting its potential to complement recommended screening programs. Clinical trial identifier: NCT02889978.